With tests in short supply, some hospitals are creating homegrown versions in their own labs. The pandemic may prove how essential such efforts are.
In theory, smart microscopic particles could evade defenders and home in on cancer targets. Will reality catch up to the hype?
Proto’s first 10 years saw policy reforms, genomic gains and a deluge of new data. What next?